---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-020590"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:51:20.313918+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aytu refinances $15M term loan to $13M at ~12.4%, saving $1.3M interest

## Summary
- New $13M Eclipse term loan at SOFR+7% (~12.4%), replacing $15M Avenue loan at ~15.9%.
- Interest rate reduced ~350 bps, saving ~$1.3M over loan life; maturity extended to June 2028.
- Revolving credit facility extended to June 2028 with max borrowing capacity increased to $14.5M.
- Received $3.5M from exercise of 2.17M warrants at $1.59; $2M used to pay down term loan.
- Shares outstanding 5,972,327 as of June 18, 2024.

## SEC filing metadata
- accession: 0001437749-24-020590
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774924020590/0001437749-24-020590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774924020590/aytu20240607c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-020590
- JSON: https://secwatch.observer/filing/0001437749-24-020590.json
- Plain text: https://secwatch.observer/filing/0001437749-24-020590.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.